Sylvester Comprehensive Cancer Center

  • 20220922 - Benedetto Pasquale

  • Investigator:
    Pasquale Benedetto
    RCname Email

    Coordinator:

    IRB: 20220922

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: Exelixis Pharmaceuticals

    Enrolling Sites:

    Sylvester

    Title:

    A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

    Eligibility Criteria - NCT05176483 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231136 - Bilusic Marijo

  • Investigator:
    Marijo Bilusic
    RCname Email

    Coordinator:

    IRB: 20231136

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Bladder,Kidney,Other Female Genital,Prostate

    Sponsor: Marengo Therapeutics

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that

    Eligibility Criteria - NCT05592626 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220774 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    Coordinator:

    IRB: 20220774

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Brain and Nervous System

    Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Safety Lead In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Glioma

    Eligibility Criteria - NCT05484622 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240209 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    Coordinator:

    IRB: 20240209

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Brain and Nervous System

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    Single-Patient Expanded Access Request (Compassionate Use) for the Treatment of Recurrent, BRAF V600E mutant, WHO Grade 2 Pleomorphic Xanthoastrocytoma with ABM-1310

  • 20231030 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:

    IRB: 20231030

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Colon,Rectum

    Sponsor: Iterion Therapeutics

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma

    Eligibility Criteria - NCT05797805 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220167 - Kuker Russ

  • Investigator:
    Russ Kuker
    RCname Email

    Coordinator:

    IRB: 20220167

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Prostate

    Sponsor: ETCTN

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

    Eligibility Criteria - NCT04071236 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210977 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20210977

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: Nuvalent

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)

    Eligibility Criteria - NCT05118789 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230307 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20230307

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Larynx,Lip, Oral Cavity and Pharynx,Lung,Other Respiratory and Intrathoracic Organs

    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Open-Label, Dose Escalation And Dose Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Anti Tumor Activity Of Pf-07799933 (Arry-440) As A Single Agent And In Combination Therapy In Participants 16 Years And Older With

    Eligibility Criteria - NCT05355701 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230559 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20230559

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: PMV Pharmaceuticals Inc

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    Eligibility Criteria - NCT04585750 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210034 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:

    IRB: 20210034

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Esophagus,Lung,Melanoma, skin,Ovary,Prostate,Unknown Sites

    Sponsor: Dragonfly Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With L

    Eligibility Criteria - NCT04423029 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230990 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:

    IRB: 20230990

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: TScan Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic So

    Eligibility Criteria - NCT05973487 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231004 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:

    IRB: 20231004

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: TScan Therapeutics

    Enrolling Sites:

    Aventura
    Sylvester
    UMH

    Title:

    Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors

    Eligibility Criteria - NCT05812027 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210890 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:

    IRB: 20210890

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: Exelixis Pharmaceuticals

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

    Eligibility Criteria - NCT03845166 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220554 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:

    IRB: 20220554

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: Imugene Limited

    Enrolling Sites:

    Sylvester

    Title:

    Protocol Title: A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors

    Eligibility Criteria - NCT05346484 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230681 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:

    IRB: 20230681

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: Arcus Biosciences

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy and in combination therapies in participants with clear cell renal cell carcinoma and other solid tu

    Eligibility Criteria - NCT05536141 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230988 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:

    IRB: 20230988

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Colon,Kidney,Ovary,Rectum

    Sponsor: DynamiCure Biotechnology

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

    Eligibility Criteria - NCT05785754 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191009 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:

    IRB: 20191009

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Bones and Joints,Lip, Oral Cavity and Pharynx

    Sponsor: HOOKIPA PHARMA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

    Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220773 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:

    IRB: 20220773

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Colon,Rectum

    Sponsor: Bexion Pharmaceuticals

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma

    Eligibility Criteria - NCT05322590 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221385 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:

    IRB: 20221385

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Breast,Esophagus,Eye and Orbit,Melanoma, skin,Stomach

    Sponsor: TSB

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes TIL ) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)

    Eligibility Criteria - NCT05576077 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231144 - Rodriguez Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    Coordinator:

    IRB: 20231144

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Esophagus,Lung

    Sponsor: Takeda

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in

    Eligibility Criteria - NCT05070247 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201378 - Tang Jennifer

  • Investigator:
    Jennifer Tang
    RCname Email

    Coordinator:

    IRB: 20201378

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Other Skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIES ARTACUS

    Eligibility Criteria - NCT04349436 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201373 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    Coordinator:

    IRB: 20201373

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Hodgkin Lymphoma,Lip, Oral Cavity and Pharynx,Lung,Melanoma, skin,Soft Tissue

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

    Eligibility Criteria - NCT03860272 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220980 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    Coordinator:

    IRB: 20220980

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple

    Sponsor: IDRX

    Enrolling Sites:

    Sylvester

    Title:

    A First-In-Human (FIH) Study Of Idrx-42 In Participants With Metastatic And/Or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Eligibility Criteria - NCT05489237 *This information has been extracted from " www.clinicaltrials.gov"

  • ATRC-101-A01 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone +1 (786) 5828551

    IRB: 20200938

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Breast,Colon,Lung,Melanoma, skin,Ovary

    Sponsor: Atreca Inc

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malignancies

    Eligibility Criteria - NCT04244552 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230286 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:

    IRB: 20230286

    SDG: Phase I (Non LLM)
    Disease Site(s):

    Bladder,Bones and Joints,Breast,Kidney,Lung,Prostate

    Sponsor: SILLAJEN INC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors

    Eligibility Criteria - NCT05768932 *This information has been extracted from " www.clinicaltrials.gov"